Last but not least: BFL-1 as an emerging target for anti-cancer therapies

Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma

(2022) Hilmar Quentmeier et al.   Scientific Reports

Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells

(2022) Xuexin Feng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML

(2022) Kotoko Yamatani et al.   Translational Oncology

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

(2022) Lahiru Gangoda et al.   Cell Death & Disease

BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified

(2021) Mario L. Marques-Piubelli et al.   Blood Cancer Journal

lncRNA PANTR1 Upregulates BCL2A1 Expression to Promote Tumorigenesis and Warburg Effect of Hepatocellular Carcinoma through Restraining miR-587

(2021) Xirui Ma et al.   Journal of Immunology Research

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1

(2021) Ingrid Spaan et al.   Cancers

HDAC Inhibition Effectively Induce Apoptosis in Diffuse Large B Cell Lymphoma with High Bfl-1

(2021) Eunchae Park et al.   BLOOD

Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL

(2020) Marco Vincent Haselager et al.   BLOOD

The pro-survival Bcl-2 family member A1 delays spontaneous and FAS ligand-induced apoptosis of activated neutrophils

(2020) Robyn L. Schenk et al.   Cell Death & Disease

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas

(2020) Scott Boiko et al.   BLOOD

Tertiary Structural Motif Sequence Statistics Enable Facile Prediction and Design of Peptides that Bind Anti-apoptotic Bfl-1 and Mcl-1

(2019) Vincent Frappier et al.   STRUCTURE

Genetic characterization of ABT-199 sensitivity in human AML

(2019) Richard Bisaillon et al.   LEUKEMIA

Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis

(2018) Selma Tuzlak et al.   FEBS Journal

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma

(2018) A. Esteve-Arenys et al.   ONCOGENE

Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor

(2018) Edward P. Harvey et al.   STRUCTURE

Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16high CD62Ldim immunosuppressive subset

(2018) Enrique Podaza et al.   INTERNATIONAL JOURNAL OF CANCER

Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer

(2018) Rachel M. Guerra et al.   Cell Reports

The novel double-hit, t(8;22)(q24;q11)/ MYC - IGL and t(14;15)(q32;q24)/ IGH - BCL2A1 , in diffuse large B-cell lymphoma

(2017) Takashi Akasaka et al.   Cancer Genetics

The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis

(2015) Yan-Wei Hu et al.   APOPTOSIS

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

(2015) R. Thijssen et al.   HAEMATOLOGICA

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

(2015) R. Thijssen et al.   HAEMATOLOGICA

Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity

(2014) R. W. Rooswinkel et al.   BLOOD

Peptide Ligands for Pro-survival Protein Bfl-1 from Computationally Guided Library Screening

(2013) Sanjib Dutta et al.   ACS Chemical Biology

BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

(2013) Rizwan Haq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice

(2012) E. Ottina et al.   BLOOD

Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma

(2012) W. Cruz-Munoz et al.   CANCER RESEARCH

Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1

(2012) Daniela Senft et al.   PLoS One

HTLV-1 Propels Thymic Human T Cell Development in “Human Immune System” Rag2-/- gamma c-/- Mice

(2011) Julien Villaudy et al.   PLoS Pathogens

The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1

(2010) M Jenal et al.   LEUKEMIA

C-terminal Residues Regulate Localization and Function of the Antiapoptotic Protein Bfl-1

(2009) Gaelle Brien et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

(2009) L J Beverly et al.   ONCOGENE

Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma

(2009) Chun-Feng Lee et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

(2008) M. Vogler et al.   BLOOD

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis

(2008) Adam I Riker et al.   BMC Medical Genomics

Completing the family portrait of the anti-apoptotic Bcl-2 proteins: Crystal structure of human Bfl-1 in complex with Bim

(2008) Maria Dolores Herman et al.   FEBS LETTERS

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY